

Effects of Montmorency tart cherry (*L. Prunus Cerasus*) consumption on nitric oxide biomarkers and exercise performance.

Keane, KM¹., Bailey, SJ²., Vanhatalo, A.³, Jones, AM³., Howatson, G^{1,4}.

¹Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom;

²School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom;

³Sport and Health Sciences, St. Luke's Campus, University of Exeter, Exeter, United Kingdom;

⁴Water Research Group, School of Environmental Sciences and Development, Northwest University, Potchefstroom, South Africa

Running head: Montmorency tart cherry consumption and exercise performance

Corresponding Author:

Karen Keane

Department of Sport, Exercise and Rehabilitation

Faculty of Health and Life Sciences

Northumbria University

Newcastle upon Tyne, UK

Tel: 00 44 (0) 191 227 7086

Email: k.keane@northumbria.ac.uk

Abstract

The purpose of this study was to investigate the effects of Montmorency tart cherry juice (MC) on nitric oxide (NO) biomarkers, vascular function and exercise performance. In a randomized, double blind, placebo (PLA) – controlled, crossover study, 10 trained cyclists (mean \pm SD; $\dot{V}O_{2\text{peak}}$ 59.0 ± 7.0 ml/kg/min) acutely ingested 30 mL of either MC or PLA following dietary restrictions of polyphenol-rich compounds, and completed 6 min moderate- and severe-intensity cycling bouts 1.5 h post ingestion on two occasions for each experimental condition. The severe-intensity cycling test was continued to exhaustion on one occasion and immediately followed by a 60 s all-out sprint on the other occasion. Blood pressure, pulse wave measures, tissue oxygenation index and plasma nitrite concentration were assessed pre and 1.5 h post ingestion. Time to exhaustion was not different between conditions ($P > 0.05$), but peak power over the first 20 s (363 ± 42 vs. 330 ± 26 W) and total work completed during the 60 s all-out sprint (21 ± 3 vs. 19 ± 3 kJ) were 10% higher in the MC trial compared to the PLA trial ($P < 0.05$). Systolic blood pressure was 5 ± 2 mmHg lower 1.5 h post MC supplementation compared to PLA supplementation ($P < 0.05$). There were no differences in pulse wave measures, plasma nitrite concentration or tissue oxygenation between the MC and PLA trials ($P > 0.05$). These results suggest that acute supplementation with MC can lower blood pressure and improve some aspects of exercise performance, specifically end-sprint performance, in trained cyclists.

Keywords: Tart cherries, exercise performance, blood pressure, nitric oxide

Aix	Augmentation index
ANOVA	Analysis of variance
AOX	Antioxidant
BP	Blood pressure
CV	Coefficient of variation
DBP	Diastolic blood pressure
GET	Gas exchange threshold
HbO ₂	Oxygenated-haemoglobin
HHb	De-oxygenated-haemoglobin
LSD	Least significant difference

MRT	Mean response time
MC	Montmorency tart cherries
NIRS	Near-infrared spectroscopy
NO	Nitric Oxide
NO ₂ ⁻	Nitrite
NO ₃ ⁻	Nitrate
eNOS	Endothelial nitric oxide synthase
PLA	Placebo
PWA	Pulse wave analysis
PWV	Pulse wave velocity
SBP	Systolic blood pressure
TOI	Tissue oxygenation index
$\dot{V}CO_2$	CO ₂ production
$\dot{V}O_2$	O ₂ uptake

1 **Introduction**

2 Montmorency tart cherries (MC) are a rich source of polyphenols ¹⁻³ including the flavonoids
3 isorhamnetin, kaempferol, quercetin, catechin and anthocyanins ^{4,5}. It has been well
4 documented that these plant compounds are associated with beneficial anti-inflammatory ⁶,
5 antioxidant ⁷ (AOX), immunomodulatory and vasodilatory properties ⁸. Previous studies
6 demonstrated the positive effects of MC concentrate on indices of cardiovascular function
7 that included increased cell migration ⁹, cerebral blood flow ¹⁰ and reduced systolic blood
8 pressure at rest^{10,11}. These effects might be mediated, in part by the ability of polyphenols to
9 facilitate endothelial nitric oxide synthase (eNOS) phosphorylation, thereby increasing
10 endogenous nitric oxide (NO) production ¹². However, an increase in NO biomarkers has not
11 been demonstrated with polyphenol-rich MC.

12 An increased muscle blood flow may increase the oxidative energy contribution over the
13 initial stages of exercise and reduce the development of the $\dot{V}O_2$ slow component (a
14 progressive increase in O_2 uptake ($\dot{V}O_2$) as high intensity exercise is continued) ¹³.
15 Supplementation with MC might have the potential to improve aspects of the dynamic $\dot{V}O_2$
16 response during exercise by enhancing endothelial function and, hence, have a positive effect
17 on performance. In addition, cyanidin-3-glucoside, an anthocyanin found in abundance in
18 MC concentrate ³, has been shown to increase endothelial NO synthase (eNOS) expression
19 and decrease inducible NO synthase (iNOS) expression ¹⁴. Such changes in the balance
20 between eNOS and iNOS expression/activity would favour the bioavailability of the
21 vasoactive NO. Therefore, if MC does increase NO bioavailability, it is possible that muscle
22 O_2 delivery and/or its intramuscular distribution might be enhanced which, in turn, could be
23 advantageous at the onset of exercise and during maximal exercise. Further to these
24 mechanisms, other compounds in tart Montmorency cherries such as quercetin (which is
25 reported to be present in MC ¹⁵) binds and antagonises the adenosine receptor, which could
26 improve performance in a caffeine-like manner ¹⁶. Similarly, MC concentrate is rich in AOX
27 compounds that also have the potential to augment performance ¹⁷.

28 Despite the potential vasodilatory and AOX properties of tart cherries, only two studies have
29 investigated the effect of tart Montmorency cherry supplementation on continuous exercise
30 capacity and performance. Clifford and colleagues ¹⁸ investigated the influence of different
31 sources of polyphenols on sub-maximal cycling and time trial performance. Supplementation
32 with 200 mg of dried Montmorency cherry capsules for three days, did not improve cycling

33 time trial performance, heart rate, respiratory exchange ratio, gross mechanical efficiency,
34 oxygen consumption, or blood [lactate] in moderately trained cyclists ($\dot{V}O_{2\text{peak}}$ 52.4 ± 8.7
35 ml/kg/min). In contrast, when participants were supplemented with powdered tart cherry
36 capsules for 10 days, half-marathon completion times were 13% faster than their placebo
37 counterparts¹⁹, although the mechanism for this improvement remains unclear. It should be
38 noted that the actual race pace was slower compared to the projected race pace in both groups,
39 but the difference tended to be smaller in the tart cherry group compared to the placebo group.
40 Furthermore, the authors of this study acknowledged that the participants were matched
41 based on average reported race pace, and therefore there might be some variability amongst
42 groups. As a result, further studies with a strong study design are needed to evaluate if
43 supplementation with tart cherries can provide benefits to exercise performance.

44 Similar performance-enhancing findings have been reported in other studies where
45 polyphenolic content of a fruit-derived supplement is similar to tart cherries^{20,21}. Kang and
46 colleagues²⁰ reported that oligomerized lychee fruit extract increased the anaerobic threshold
47 by 7.4%. More recently, Cook et al.²¹ reported that following a seven-day intake of New
48 Zealand blackcurrant extract, there was an improvement in cycling time-trial performance by
49 2.4%. The authors speculated that this improvement might have been the result of improved
50 endothelial function and increased peripheral blood flow. Conversely, in another study²²,
51 supplementation with a polyphenol antioxidant for 1 week failed to improve exercise
52 performance, cardiovascular function, and thermoregulatory control in well-trained cyclists.
53 The lack of improvement in exercise performance may be related to the training status of the
54 subjects, exercise modality, and/or the experimental conditions under which performance was
55 assessed.

56 Although the potential beneficial role of MC in expediting exercise recovery has been
57 unequivocally demonstrated^{23,24}, it is still unclear whether acute MC supplementation can
58 improve endurance exercise performance. Given that most polyphenol compounds are either
59 absorbed or excreted quickly^{9,10,25}, longer-term (10-day) supplementation periods¹⁹ may not
60 be necessary to observe improvements in performance. Furthermore, the potential
61 mechanisms that might underpin any ergogenic effects of MC consumption are yet to be fully
62 resolved. Therefore, the purpose of this study was to investigate the effects of acute MC
63 supplementation on plasma NO_2^- concentration ($[\text{NO}_2^-]$), a sensitive marker of NOS activity
64²⁶, as well as blood pressure, $\dot{V}O_2$ kinetics, muscle oxygenation and exercise performance
65 using a double-blind, cross-over experimental study design. We also used near-infrared

66 spectroscopy to provide insight into the matching between skeletal muscle O₂ delivery and
67 utilisation ²⁷ and, therefore the potential underlying mechanisms for improvement in $\dot{V}O_2$
68 kinetics or exercise performance following MC supplementation.

69 **Methods**

70 **Participants**

71 Eleven trained male cyclists volunteered to take part in the study, but one participant
72 withdrew after the second study day (mean \pm SD age; 28 ± 7 years, stature 1.83 ± 0.06 m,
73 body mass 78.0 ± 8.5 kg and $\dot{V}O_{2peak}$ 59.0 ± 7.0 ml/kg/min). Exclusion criteria for the study
74 were: $\dot{V}O_{2peak} < 50$ ml/kg/min (determined on visit 1), smoking, food allergy (as discussed
75 with research team), history of gastrointestinal, renal or cardiovascular disease and current
76 use of any food supplementations. All participants provided written, informed consent prior
77 to the commencement of the study. For 24 h prior to and for each of the testing days,
78 participants were asked to avoid strenuous exercise, alcohol, caffeine, nutritional supplements
79 and any anti-inflammatory drugs. Participants were instructed to follow a low phenolic diet
80 for 24 h prior to each arm of the trial by avoiding fruits, vegetables, tea, coffee, alcohol,
81 chocolate, cereals, wholemeal bread, grains and spices and were asked to refrain from
82 strenuous exercise. Compliance with the dietary restrictions was monitored with a
83 standardised, self-reported dietary record. Participants were asked to arrive at the laboratory
84 in a rested and fully hydrated state, ≥ 10 h postprandial. All tests were performed at the same
85 time of day. The study was conducted in accordance with the Helsinki Declaration and
86 ratified by the University's Research Ethics Committee.

87 **Study Design**

88 Participants were required to report to the laboratory on five occasions over a 4-5 week
89 period to complete the experimental testing (1 familiarization / $\dot{V}O_{2peak}$ visit and 4
90 experimental visits). On the first visit to the laboratory, participants completed a ramp
91 incremental exercise test for determination of the gas exchange threshold (GET) and peak
92 $\dot{V}O_2$ ($\dot{V}O_{2peak}$). Participants were also familiarized with the two exercise performance tests
93 employed in the study on this visit to avoid any order effect on the performance results as a
94 consequence of a potential "learning effect". Participants then returned to the laboratory on
95 visits 2, 3, 4 and 5 to complete the experimental testing (MC \times 2 trials, PLA \times 2 trials).
96 During these tests, resting blood pressure, arterial stiffness, pulmonary $\dot{V}O_2$ kinetics during
97 moderate and severe intensity exercise, muscle oxygenation, and exercise performance were

98 assessed, and venous blood samples were obtained. The MC concentrate and placebo (PLA)
99 drinks were administered in a randomized order as part of a double-blind, crossover
100 experimental design. Each supplementation day was separated by at least 3 days, but no
101 more than 7 days.

102 ***Incremental Test.***

103 During the first laboratory visit, participants completed a ramp incremental cycle test on an
104 electronically braked cycle ergometer (Lode Excalibur Sport, Groningen, The Netherlands).
105 Initially, participants performed 3 min of baseline cycling at 0 W, after which the work rate
106 was increased by 30 W/min until the limit of tolerance. The participants cycled at a self-
107 selected pedal rate, which, along with saddle and handle bar heights and configuration, was
108 recorded and reproduced in subsequent tests. Breath-by-breath pulmonary gas exchange data
109 were collected continuously during the incremental tests and averaged over consecutive 10 s
110 periods. The $\dot{V}O_{2peak}$ was taken as the highest 30 s rolling mean value attained prior to the
111 participant's volitional exhaustion in the test. The GET was determined as 1) the first
112 disproportionate increase in $\dot{V}CO_2$ production ($\dot{V}CO_2$) from visual inspection of individual
113 plots of $\dot{V}CO_2$ and $\dot{V}O_2$, and an increase in expired ventilation $\dot{V}_E/ \dot{V}O_2$ with no increase in
114 $\dot{V}_E/ \dot{V}CO_2$. The work rate that would require 90% of the GET (moderate – intensity exercise)
115 and 70% Δ (GET + 70% of the difference between the work rate at the GET and $\dot{V}O_{2peak}$;
116 severe intensity exercise) were calculated. The $\dot{V}O_2$ peak attained in the ramp incremental
117 test was 4.56 ± 0.3 l/min, which equated to a relative $\dot{V}O_2$ peak of 59.0 ± 7.0 ml·kg⁻¹·min⁻¹.
118 The work rates that corresponded to 90% GET and 70% Δ were 121 ± 19 and 303 ± 28 W,
119 respectively. The mean response time (MRT) for $\dot{V}O_2$ during ramp exercise was taken into
120 account, specifically two-thirds of the ramp rate was deducted from the work rate at GET and
121 peak $\dot{V}O_2$ (i.e., $20W^{28}$).

122

123 Following the incremental test and a 45-minute rest, participants were familiarized with the
124 exercise tests. Participants completed a moderate- intensity and severe-intensity, step test
125 finishing with an all-out sprint followed (after a 30-minute passive recovery period) by a
126 severe-intensity constant-work-rate step exercise test to the limit of tolerance.

127 ***Experimental tests.***

128 On all subsequent visits, participants were required to rest in a seated position for 10 min in
129 an isolated room. Thereafter, baseline blood pressure of the brachial artery was measured
130 using an automated sphygmomanometer (M10-IT Omron Healthcare, UK) according to

131 British Hypertension Society guidelines. Additionally, pulse wave velocity and pulse wave
132 analysis were determined by using Arterial Tonometry (SphygmoCor CPV system, ScanMed
133 Medical, UK). Three measurements were taken, and the mean of the measurements were
134 calculated. A venous blood sample was then collected into a lithium-heparin tube and
135 centrifuged at 4,000 rpm at 4°C for 10 min, within 2 min of collection. Lithium-heparin
136 plasma was subsequently extracted and immediately frozen at -80°C for later analysis of
137 [NO₂⁻] in duplicate via ozone-based chemiluminescence²⁹.

138

139 Participants were then provided with standardised breakfast. Descriptive measures and a
140 Physical Activity Level of 1.7 was used to calculate the participant's individual resting
141 energy expenditure (Schofield Equation, 1985). This subsequently identified the amount of
142 cereal (Rice Snaps, Tesco, Manchester, UK) and semi-skimmed milk (1g/kg/bm) each
143 individual needed to consume to meet 10% of their daily energy requirements. This
144 standardised fixed-energy breakfast meal consisted of a cereal: milk ratio of 30 g: 120 ml and
145 delivered fat, protein and carbohydrate with a macronutrient composition of 14, 14 and 72%,
146 respectively³⁰. One-hour post breakfast consumption, participants received the intervention
147 drink. Ninety minutes after ingestion of the supplement, vascular measures were reassessed
148 and participants completed one of the two cycle tests described below, as published
149 pharmacokinetic data have shown that this time frame should coincide with peak plasma
150 concentrations of phenolic acids following MC supplementation^{9,11}.

151

152 The exercise protocol consisted of three "step" exercise tests including two moderate
153 intensity step tests followed by one severe-intensity exercise bout. All participants performed
154 a total of four bouts of moderate intensity exercise and two bouts of severe-intensity exercise
155 for each experimental condition; this protocol replicated previously work³⁰. Each transition
156 began with 3 min of baseline cycling at 20 W before an abrupt transition to the target work
157 rate. Each moderate intensity bout lasted 6 min. A passive recovery of 5 min separated the
158 transitions. On two of the study visits (one occasion for each supplement), participants
159 cycled for 6 min at a severe-intensity constant work rate (70% Δ), followed immediately by a
160 60 s all-out sprint at maximum effort. The resistance on the pedals during this sprint was set
161 using the linear mode of the Lode ergometer, so that each participant would attain the power
162 output calculated to be 50% Δ when considering the participants preferred cadence (linear
163 factor = power/preferred cadence²). Participants were provided with a 5 s countdown prior to
164 the sprint. On the other two study visits (one occasion for each supplement), the severe-

165 intensity constant-work-rate bout was continued to the limit of tolerance. The time to task
166 failure was used as a measure of exercise tolerance and was immediately recorded when the
167 pedal rate fell by > 10 rpm below the required pedal rate.

168 **Treatments and dietary control**

169 Participants consumed either 60 ml of commercially available MC concentrate
170 (CherryActive®, Hanworth, UK) or fruit-flavoured cordial in a double-blind, cross-over
171 manner. The choice to use 60 ml was based on previous work that showed a greater uptake
172 of anthocyanin and phenolic acids *in vivo* post-consumption when compared to a 30 ml dose
173 ^{3,9,11}. The concentrate was diluted with 100 ml of water prior to consumption. The PLA
174 supplement consisted of a commercially available, low fruit (<1%) cordial (Kia Ora, Coca
175 Cola Enterprises, Uxbridge, UK) cordial mixed with water, whey protein isolate (Arla Foods
176 Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK), to match the MC
177 concentrate for volume and macronutrient content (Energy = 204 kcal, volume = 60 ml,
178 carbohydrates = 49 g, protein = 2.2 g and fat = 0 g).

179

180 Prior to study commencement, it was explained to participants that the aim of the study was
181 to investigate the effect of a fruit juice on vascular function. As a result, they were unaware
182 which beverage was the experimental drink. There were no adverse events reported in
183 response to the intervention products. Subjects consumed all doses of the supplement for each
184 experimental condition, and all participants complied with the low-polyphenolic experimental
185 diet according to the food diaries.

186 **Measurements**

187 During all tests, pulmonary gas exchange and ventilation were measured breath-by-breath.
188 Participants wore a nose clip and breathed through a low-dead-space, low-resistance
189 mouthpiece-and-impeller turbine assembly. Following calibration according to
190 manufacturer's recommendations, the inspired and expired gas volume was continuously
191 sampled at 100 Hz; gas concentration signals were continuously sampled at 100 Hz using
192 paramagnetic (O₂) and infrared (CO₂) analyzers (Oxycon, Care Fusion, Rolle, Switzerland).
193 For data analysis, the moderate bouts of exercise were exported in 10-s averages and then
194 averaged for all bouts. End-exercise $\dot{V}O_2$ (average over the last 30 s and 60 s of the bout),
195 baseline $\dot{V}O_2$ (average over the 60 s prior to exercise) and the amplitude (the difference
196 between the end-exercise and baseline $\dot{V}O_2$) were analysed. For the severe bouts of exercise,
197 the data were exported in 10-s averages and then all bouts were averaged. Baseline $\dot{V}O_2$

198 (average over the 60 s prior to exercise), the $\dot{V}O_2$ at 120 s (the average from 110 s to 130 i.e.
199 120 s +/- 10 s) and the end-exercise $\dot{V}O_2$ (the average over the last 30 s of the bout) were
200 identified. The peak $\dot{V}O_2$ was identified using the end- exercise $\dot{V}O_2$. Furthermore, the
201 difference between the baseline and 120 s $\dot{V}O_2$ provides a surrogate for the fundamental
202 amplitude whilst the difference between $\dot{V}O_2$ at 120 s and end-exercise (exhaustion) was used
203 as a surrogate of the $\dot{V}O_2$ slow component.

204 The oxygenation status of the vastus lateralis of the right leg was monitored near-infrared
205 spectroscopy system (NIRS; INVOS 5100C, Somanetics, Troy, MI, USA) at two different
206 wavelengths (765 nm and 855 nm). The intensity of the transmitted light was continuously
207 recorded at 1 Hz. Based on the absorption and scattering coefficients of light at each
208 wavelength, determined by Beer–Lambert Law, concentrations were estimated for oxy
209 (HbO_2), deoxy (HHb), and total haemoglobin. The leg was initially cleaned around the belly
210 of the muscle, and the optodes were placed 20 cm above the fibular head. The probes were
211 secured to the skin surface and covered with an elasticized, tensor bandage to minimize the
212 influence of extraneous light, and to avoid movement of the probe relative to the skin, while
213 allowing unrestricted movement. The NIRS data were acquired continuously throughout the
214 exercise protocol and output every 5 s and recorded for later offline analysis. The NIRS data
215 output was time stamped at the start of each task segment to assure that data corresponded to
216 the relevant period of task performance. To provide information on muscle oxygenation,
217 NIRS data was averaged at the time points of interest and relative concentration changes in
218 HbO_2 and HHb were calculated.

219 The tissue oxygenation index (TOI) was calculated using the following equation³⁰

$$220 \quad TOI = \frac{[HbO_2]}{[HbO_2] + [HHb]} \times 100 \quad \text{Equation 1}$$

222 Pulse wave velocity (PWV) and pulse wave analysis (PWA) were determined by using
223 Arterial Tonometry (SphygmoCor CPV system, ScanMed Medical, UK). The aortic pulse
224 waveform and augmentation index were derived at the radial artery and PWV was
225 determined between carotid and femoral sites. A pencil-type probe was used for all
226 measurements and was held at the base of the neck over the carotid artery and at the inguinal
227 crease over the right femoral artery. Recordings were taken when a reproducible signal was
228 obtained with a high amplitude excursion. The distance between carotid and femoral sites

229 was measured and electrocardiogram gating permitted the time lapse between pulse waves at
230 the carotid and femoral sites to be calculated. Inter- and intra-trial % coefficient of variation
231 (CV) for this method was 3.3 and 3.1%, respectively.

232 During the exercise trials, a blood sample was collected from a fingertip into a capillary tube
233 at baseline, over the 20 s preceding the step transition in work rate, the 20 s preceding the
234 completion of 360 s of moderate- and severe-intensity cycling exercise, immediately
235 following the 60-s all-out sprint and immediately after exhaustion during the severe-intensity
236 constant-work-rate trial. These whole blood samples were analysed to determine blood
237 lactate (Biosen C_Line, EKF Diagnostic, Barleben, Germany). Intra-sample coefficient of
238 variation for this instrument was 1.8%.

239 **Plasma [nitrate] and [nitrite] determination**

240 All glassware, utensils, and surfaces were rinsed with deionized water to remove residual NO
241 intermediates prior to $[\text{NO}_2^-]$ and $[\text{NO}_3^-]$ analysis. Plasma samples were deproteinized using
242 zinc sulfate/sodium hydroxide precipitation prior to determination of $[\text{NO}_3^-]$. Firstly, 500 μL
243 of 0.18 N NaOH was added to 100 μL of sample followed by 5 min incubation at room
244 temperature. Subsequently, samples were treated with 300 μL aqueous ZnSO_4 (5% w/v) and
245 vortexed for 30 s before undergoing an additional 10 min incubation period at room
246 temperature. Samples were then centrifuged at 4,000 rpm for 5 min, and the supernatant was
247 removed for subsequent analysis. The $[\text{NO}_3^-]$ of the deproteinized plasma sample was
248 determined by its reduction to NO in the presence of 0.8 % (w/v) VCl_3 in 1 M HCl within an
249 air-tight purging vessel. Plasma samples were introduced to the vessel via 50 μL injections
250 into the septum at the top of the vessel. The spectral emission of electronically excited
251 nitrogen dioxide, derived from the reaction of NO with ozone, was detected by a
252 thermoelectrically cooled, red-sensitive photomultiplier tube housed in a Sievers gas-phase
253 chemiluminescence nitric oxide analyzer (Sievers NOA 280i. Analytix Ltd, Durham, UK).
254 The $[\text{NO}_3^-]$ was determined by plotting signal (mV) area against a calibration plot of sodium
255 nitrate standards. The $[\text{NO}_2^-]$ of the undiluted (non-deproteinized) plasma was determined by
256 its reduction to NO in the presence of glacial acetic acid and aqueous NaI (4% w/v) from
257 sodium nitrite standards. 100 μL injections were used for plasma $[\text{NO}_2^-]$ determination.

258 **Statistical Analysis**

259 Statistical analysis was performed using PASW Statistics 21.0 for Windows (SPSS, Inc.,
260 Chicago, IL.). All group characteristics were reported as means \pm standard deviations, unless

261 otherwise stated. A 2 (MC vs. PLA) \times 2 (pre vs. post) repeated measures analysis of variance
262 (ANOVA) was employed to assess between-intervention differences in $\dot{V}O_2$, NIRS-TOI,
263 blood pressure, arterial stiffness and lactate. Mauchly's Test of Sphericity was used to check
264 homogeneity of variance for all ANOVA analyses and where necessary, violations of the
265 assumption were corrected using the Greenhouse-Geisser adjustment. Significant main
266 effects were followed up using LSD *post hoc* analysis. Exercise performance and NO₂- and
267 NO₃- were analysed using a paired samples t-test. Statistical significance was accepted when
268 $P < 0.05$.

269 **Results**

270 Eleven physically active males volunteered to take part in the study, but one participant
271 voluntarily withdrew after the second study day (n=10).

272 **Pulmonary $\dot{V}O_2$ kinetics**

273 The pulmonary $\dot{V}O_2$ data for the moderate- and severe-intensity cycle tests are reported in
274 Table 1. There were no significant between-supplement differences for the baseline and end-
275 exercise $\dot{V}O_2$ during the moderate-intensity step exercise tests ($P > 0.05$). Accordingly, the
276 fundamental $\dot{V}O_2$ amplitude was not significantly different between the conditions ($0.55 \pm$
277 0.09 and 0.60 ± 0.07 l/min with MC concentrate and PLA respectively, $P > 0.05$).

278

279 The baseline and end-exercise $\dot{V}O_2$ during severe-intensity exercise were not significantly
280 impacted by the dietary interventions employed in this investigation ($P > 0.05$ for all
281 comparisons). The $\dot{V}O_2$ at exhaustion was not significantly different between experimental
282 conditions and was also not significantly different from the $\dot{V}O_{2peak}$ attained in the ramp
283 incremental test ($P > 0.05$). No significant differences were reported between MC and PLA
284 in $\dot{V}O_2$ amplitudes from baseline to 120 s of exercise. No differences in $\dot{V}O_2$ slow component
285 were observed across the experimental conditions (Table 1). There were no differences in
286 $\dot{V}CO_2$ between the conditions during moderate- or severe-intensity cycle exercise ($P > 0.05$
287 for all comparisons).

288

289 >>>> **Table 1** <<<<<

290 **Exercise performance**

291 The time to exhaustion during the severe-intensity constant-work-rate cycle trials (the
292 exercise tolerance test) are presented in Fig 1; while the power profiles for the two

293 experimental conditions during the 60-s all-out sprint that followed the 6-min bout of severe
294 intensity exercise (the exercise performance test) are presented in Fig 2. There were no
295 significant differences in time to exhaustion during the exercise tolerance test between the
296 MC (772 ± 34 s) and the PLA conditions (733 ± 34 s, $P = 0.323$). A significant main effect
297 for supplement was observed for the peak power over the first 20 s and total work completed
298 during the 60-s all-out sprint that followed the 6 min severe intensity preload ($P < 0.002$).
299 Follow-up analyses demonstrated that, compared with PLA, MC concentrate supplementation
300 increased the test peak power by 9.5% (363 ± 42 vs. 330 ± 26 W, $P = 0.034$; Fig 2) and the
301 total work completed during the 60 s sprint by 10% between conditions (21 ± 3 vs. 19 ± 3 kJ,
302 $P = 0.021$).

303

304 >>>> **Figure 1** <<<<

305 >>>> **Figure 2** <<<<

306

307 **NIRS**

308 The tissue oxygenation index data during moderate- and severe-intensity cycle exercise with
309 PLA and MC supplementation are reported in Table 2. There were no significant differences
310 between the experimental conditions during the moderate or severe-intensity exercise ($P >$
311 0.05).

312 >>>> **Table 2** <<<<

313

314 **Vascular measures**

315 There was a significant interaction effect for supplement on SBP ($P < 0.05$), with follow-up
316 analyses showing that SBP was lower 1.5 h post MC supplementation, with reductions of $5 \pm$
317 2 mmHg compared to the placebo trial. No other vascular variables (DBP, mean arterial
318 pressure (MAP), PWV, augmentation index (AIx) and AIx corrected for HR at 75 bpm) were
319 altered after consumption of the MC concentrate compared to the placebo treatment. The
320 absolute values for all variables are presented in Table 3.

321

322

323

>>>> **Table 3** <<<<

324

325 **Plasma [NO₂⁻] and [NO₃⁻]**

326 Due to sampling error, blood was analysed in 8 participants. The plasma [NO₂⁻] and [NO₃⁻]
327 for the MC and PLA conditions are reported in Table 4. There were no changes for NO₂⁻ or
328 NO₃⁻ in the MC supplemented trial when compared to the placebo (P > 0.05).

329

330

>>>> **Table 4** <<<<

331

332 **Lactate**

333 There was no treatment or treatment × time interaction effect observed in blood [lactate],
334 however there was a significant time effect identified during both the exercise performance
335 and tolerance test (P < 0.001). No other differences were reported. Absolute values are
336 presented in Table 5.

337

>>>> **Table 5** <<<<

338

339

340 **Discussion**

341 The principal novel findings from this study are that, compared with an energy-matched
342 placebo, acute MC supplementation enhanced end-sprint performance following a 6 min
343 severe-intensity preload in trained cyclists without changing $\dot{V}O_2$, plasma $[NO_2^-]$ or muscle
344 oxygenation variables. In addition, SBP was lower 1.5 h post MC consumption but not with
345 PLA.

346 *Influence of MC supplementation on performance*

347 In the current study, peak power output and total work done during a 60-s sprint increased by
348 9.5 and 10%, following MC relative to the PLA supplementation. While tart cherry
349 supplementation has been shown to improve exercise recovery^{23,24} and decrease markers of
350 inflammation and oxidative stress^{1,3}, studies investigating the effects of tart cherries on
351 exercise performance are limited and equivocal. Of the two studies investigating the
352 influence of MC supplementation on exercise performance to date, one reported improved
353 performance in males completing a half marathon (21.1km) run, as evidenced by a faster
354 overall race pace compared to the PLA group¹⁹. However, as previously mentioned, there
355 were some limitations to the study design and therefore these results should be interpreted
356 with a degree of caution. While Levers et al.¹⁹ designed an experiment to assess the influence
357 of ingesting 480 mg of powdered tart cherries for 10-days, including supplementation on race
358 day up to 48-hr post-run, we investigated the effects of a single dose (60 ml) of MC
359 concentrate on exercise performance using a cross over study design. Despite the differences
360 in dosing strategies, both studies reported improvements in performance. Therefore, our
361 findings suggest that acute as well as chronic supplementation with MC concentrate has the
362 potential to improve performance, specifically end-sprint performance. Conversely, an earlier
363 study by Clifford and colleagues¹⁸ reported no difference in time trial performance in
364 moderately-trained individuals following the ingestion of 200 mg of powdered tart cherries
365 for 3-days. These conflicting findings might be due to the differences in dosing procedures
366 (480mg versus 200mg) and exercise tests performed (20 km cycling time trial versus half
367 marathon). The current investigation used a MC concentrate as opposed to the powdered
368 capsules used in both previous studies. The MC concentrate was found to contain 73.50
369 ± 0.20 mg cyanidin-3-glucoside /L and 178.75 ± 0.87 mean gallic acid equiv/L¹¹. The
370 exercise protocol used in the current study also differed to the two previous studies.

371 There were no differences observed for time to exhaustion between the MC and the PLA
372 trial in the current study. Trinity and colleagues also reported that polyphenol
373 supplementation did not improve performance during prolonged exhaustive exercise (one
374 hour of exercise including a 10 min time trial) or during shorter duration high intensity
375 exercise (time to fatigue at $\dot{V}O_{2max}$). There remains a debate surrounding the applicability
376 and repeatability of the time to exhaustion test as there is a larger day to day variability when
377 compared to a time-trial³². However, a recent addition to the literature concluded that a time
378 to exhaustion test is regarded as a more useful measure of cycling performance compared to a
379 time trial³³.

380 There were no changes in $\dot{V}O_2$, blood [lactate] or muscle oxygenation in the current study
381 suggesting that the ergogenic effects of MC supplementation were not linked to improved
382 metabolic responses or better matching of muscle O_2 supply to O_2 demand. Furthermore,
383 plasma $[NO_2^-]$ was not different between the two trials and since plasma $[NO_2^-]$ is a sensitive
384 biomarker of eNOS activity²⁶, the performance improvements with MC supplementation
385 appear to be independent of NO-mediated signalling. It is more likely that the enhanced
386 performance might be mediated through the AOX and vasodilatory properties of polyphenol-
387 rich MC. When undertaking high intensity exercise, ROS are produced causing cellular
388 damage and oxidative stress³⁴. AOX have the ability to prevent or reduce the extent of
389 oxidative damage to other molecules. It is therefore possible that the AOX effects of MC
390 concentrate were only significant when skeletal muscle contractions were most likely to be
391 compromised by increased oxidative stress³⁴. In agreement, an investigation by MacRae and
392 Mefferd³⁵ reported that the addition of a flavonoid quercetin to a liquid AOX supplement
393 significantly enhanced the AOX effect of the supplement and resulted in a 3.1% performance
394 improvement during a 30 km cycle time trial. Hence, it is possible that a combination of
395 AOX compounds may induce larger effects on exercise performance. It is also possible that
396 this increase in AOX defence from the MC concentrate relative to the PLA may have been
397 amplified by the lowering of dietary sources high in AOX's i.e. dietary restrictions imposed
398 on participants. Previous literature has reported that the baseline antioxidant profile of an
399 individual is an important determinant of the ergogenic effectiveness of an antioxidant
400 treatment³⁶.

401 Given that MC concentrate has been shown to possess numerous AOX and polyphenolic
402 compounds^{1,2}, it seems reasonable that the improvement in exercise performance in the
403 current study might be as a result of these AOX compounds. It is worth noting that MC

404 supplementation could have prolonged the duration for which the participants were in the
405 optimal cellular redox state for force production ³⁷ such that when they were required to
406 produce an all-out sprint, they produced a higher peak power and completed more work. In
407 addition, muscle blood flow is considered an important limiting factor during high intensity
408 exercise ³⁸, and it is possible that the improvement in exercise performance might be linked,
409 in part, to an increase in blood flow. Previous research has demonstrated the vasodilatory
410 effects associated with anthocyanin intake ³⁹ and more recently, MC supplementation has
411 been shown to alter vascular function and behaviour ^{9,10,11}.

412 *Influence of MC supplementation on plasma [NO₂⁻]*

413 Nitric oxide is a key regulator of vascular integrity. This multifaceted physiological
414 signalling molecule can be synthesized endogenously through NOS with plasma [NO₂⁻]
415 reflecting NOS activity ²⁶. No significant difference in plasma [NO₂⁻] was reported between
416 the MC and PLA trials in the current study. This is somewhat in agreement with the findings
417 from Keane and colleagues ¹¹, where no main effect for plasma NO₃⁻ or NO₂⁻ was observed
418 following 60 mL MC supplementation using an ELISA kit. Importantly, the lack of a change
419 in plasma [NO₂⁻] in the current study extends our previous findings by using a more sensitive
420 method to detect plasma [NO₂⁻] in the nM range and this better reflects NOS activity than
421 plasma [NO₃⁻] ²⁶. Since trained endurance cyclists were recruited in the current study, and
422 since endurance training increase NOS expression ⁴⁰, it is likely that eNOS-derived NO
423 production was already optimal in this cohort and therefore no changes were observed after
424 MC supplementation. It is also noteworthy that the resting plasma [NO₂⁻] was relatively low
425 in the current study when compared with previous literature ³¹. This could be as a result of the
426 dietary restrictions imposed on the participants on the day preceding the trial and/or a low
427 intake of nitrate-rich foods in the period leading into the trials.

428 *Influence of MC supplementation on blood pressure*

429 A primary outcome of enhanced NO synthesis is a reduction in blood pressure owing to NO-
430 induced smooth muscle relaxation ⁴¹. The current study reported a significant reduction in
431 SBP 1.5 h post MC ingestion relative to placebo, however this augmented modulation
432 occurred in the absence of changes in NO biomarkers. These results are consistent with a
433 recent study demonstrating that supplementation with the NOS substrate, L-Citrulline ³¹,
434 lowered blood pressure in the absence of a change in plasma [NO₂⁻]. Mechanistically, it
435 would appear that the lowering of BP with acute MC supplementation in the current study is

436 largely NO-independent and is more likely to be a function of the increase in circulating
437 phenolic metabolites post MC ingestion ¹¹. There was no change in arterial stiffness observed
438 in the current study. This observation is in line with previous studies reporting improved
439 SBP following MC consumption in males with early hypertension ¹¹ and middle aged adults
440 ¹⁰, with no improvement in arterial stiffness. It has previously been reported that concurrent
441 improvements in all measures of vascular function are not always observed ¹¹. Further
442 research is required to investigate the mechanisms by which MC supplementation might
443 positively affect vascular and other physiological responses.

444 A limitation of the current study is the lack of polyphenol analysis and oxidative stress
445 biomarkers. Conceivably, there are a number of mechanisms that could contribute to the
446 physiological effects exerted by MC, and further research is needed to address the underlying
447 mechanisms for these observations. In addition, participants in the current study were asked
448 to adhere to strict dietary guidelines in the days preceding the trials and future work should
449 attempt to investigate the potential synergetic effects of MC supplementation within habitual
450 dietary practices.

451 In conclusion, this study has shown that acute supplementation with MC juice can lower
452 blood pressure and improve exercise performance, specifically end-sprint performance, in
453 trained endurance cyclists. There were no changes in plasma [NO₂⁻], pulmonary $\dot{V}O_2$, or
454 muscle oxygenation after ingesting tart cherry juice so the improvements in blood pressure
455 and exercise performance in this study might be mediated through the potent antioxidant
456 properties of MC juice. The results of this study suggest that supplementation with MC
457 concentrate might represent, a practical, non-pharmacological, dietary intervention to reduce
458 blood pressure and enhance end-sprint performance in trained individuals.

459 **Perspectives**

460 The improvement in end-sprint performance in the current study could prove advantageous in
461 sporting situations where very little separates opponents. After completing exercise that was
462 deemed metabolically strenuous, participants performed better over a 60-s sprint when
463 supplemented with MC compared to placebo. Consequently, MC supplementation might be
464 of interest to athletes, coaches and applied sport scientists. Also, the marked reduction in
465 systolic blood pressure we observed with MC supports previous studies ^{10,11} and underlines
466 the potential importance of MC as an adjunct to the management of hypertension.

467

468 The Cherry Research Committee of the Cherry Marketing Institute (Lansing, MI, USA), a not
469 for profit organisation, provided support for a PhD studentship associated with this work. All
470 other elements of the study were funded by Northumbria University. The funders had no role
471 in the study design, data collection and analysis, decision to publish, or preparation of the
472 manuscript. The authors declare no conflict of interest.

473

474 **References**

- 475 1. Wang H, Nair MG, Strasburg, GM, Chang YC, Booren, AM, Gray JI, DeWitt, DL.
476 AOX and anti-inflammatory activities of anthocyanins and their aglycon, cyanidin,
477 from tart cherries. *J Nat Prod* 1999; 62(2): 294–296. doi:10.1021/np980501m
- 478 2. Seeram, NP, Momin, RA, Nair, MG, Bourquin, LD. Cyclooxygenase inhibitory and
479 AOX cyanidin glycosides in cherries and berries. *Phytomedicine* 2001, 8(5); 362–369.
480 doi:10.1078/0944-7113-00053
- 481 3. Bell, PG, Gaze, DC, Davison, GW, George, TW, Scotter, MJ, Howatson, G.
482 Montmorency tart cherry (*Prunus Cerasus L.*) concentrate lowers uric acid,
483 independent of plasma cyanidin-3-O-glucosiderutinoside. *J Funct Foods* 2014, 11; 82-
484 90
- 485 4. Kim, DO, Heo, HJ, Kim, YJ Yang, HS, Lee, CY. Sweet and sour cherry phenolics
486 and their protective effects on neuronal cells. *J Agr Food Chem* 2005, 53; 9921-9927.
- 487 5. Kirakosyan, A, Seymour, EM, Llanes, DEU, Kaufman, PB, Bolling, SF. Chemical
488 profile and AOX capacities of tart cherry products. *Food Chemistry*, 2009, 115(1);
489 20–25. doi:10.1016/j. foodchem.2008.11.042
- 490 6. Zhu, Y, Ling, W, Guo, H, Song, F, Ye, Q, Zou, T, Li, D, Zhang, Y, Li, G, Xiao, Y,
491 Liu, F, Li, Z, Shi, Z, Yang, Y. Anti-inflammatory effect of purified dietary
492 anthocyanin in adults with hypercholesterolemia: a randomized controlled trial. *Nutr*
493 *Metab Cardiovas* 2013, 23; 843–849
- 494 7. De La Cruz, AA, Hilbert, G, Mengin, V, Rivière, C, Ollat, N, Vitrac, C, Bordenave, L,
495 Decroocq, S, Delaunay, JC, Mérillon, JM, Monti, JP, Gomès, E, Richard, T.
496 Anthocyanin phytochemical profiles and anti-oxidant activities of *Vitis candicans* and
497 *Vitis doaniana*. *Phytochemical Analysis* 2013, 24; 446–452.
- 498 8. Tangney, C, Rasmussen, HE. Polyphenols, Inflammation, and Cardiovascular
499 Disease. *Curr Atheroscler* 2014, 15(5), 324. doi:10.1007/s11883-013-0324-x.
- 500 9. Keane, KM, Bell, PG, Lodge, J, Constantinou, C, Howatson, G. Phytochemical
501 uptake following human consumption of Montmorency tart cherry (*L. Prunus Cerasus*)
502 and influence of phenolic acids on vascular smooth muscle cells in vitro. *Eur J Nutr*
503 2016, 55(4): 1695-705.
- 504 10. Keane, KM, Haskell-Ramsay, CF, Veasey, RC Howatson, G. Montmorency Tart
505 cherries (*Prunus Cerasus L.*) modulate vascular function acutely, in the absence of
506 improvement in cognitive performance. *Br J Nutr* 2016, 116(11); 1935-1944

- 507 11. Keane, KM, George, TW, Constantinou, CL, Brown, MA, Clifford, T, Howatson, G.
508 Effects of Montmorency tart cherry (*Prunus Cerasus L.*) consumption on vascular
509 function in men with early hypertension. *Am J Clin Nutr* 2016, 1-9
- 510 12. Martin, S, Andriambeloson, E, Takeda, K, Andriantsitohaina, R. Red wine
511 polyphenols increase calcium in bovine aortic endothelial cells: a basis to elucidate
512 signalling pathways leading to nitric oxide production. *Brit J Pharmacol* 2002, 135;
513 1579–1587.
- 514 13. Poole, DC, Barstow, TJ, McDonough, P, Jones, AM. Control of oxygen uptake during
515 exercise. *Med Sci Sports Exerc* 2008, 40(3); 462 – 474.
- 516 14. Xu JW, Ikeda K, Yamori Y. Upregulation of endothelial nitric oxide synthase by
517 cyanidin-3-glucoside, a typical anthocyanin pigment. *Hypertension* 2004;44:217–22
- 518 15. Schaller, D.R., & Von Elbe, J.. Polyphenols in montmorency cherries. *J Food Sci*,
519 1970, 35, 762-765.
- 520 16. Alexander SP. Flavonoids as antagonists at A1 adenosine receptors. *Phytother Res*.
521 2006, 20(11):1009–12.
- 522 17. Gomez-Cabrera MC, Salvador-Pascual A, Cabo H, et al. Redox modulation of
523 mitochondriogenesis in exercise. Does antioxidant supplementation blunt the benefits
524 of exercise training? *Free Radic Biol Med*. 2015;86:37–46.
- 525 18. Clifford, T, Scott, A, Mitchell, N. The influence of different sources of polyphenols
526 on submaximal cycling and time trial performance. *Int J Sport Nutr Exerc Metab* 2013,
527 2(6); S10.
- 528 19. Levers, K, Dalton, R, Galvan, E, O'Connor, A, Goodenough, C, Simbo, S, Mertens-
529 Talcott, SU, Rasmussen, C, Greenwood, M, Riechman, S, Crouse, S, Kreider, RB.
530 Effects of powdered Montmorency tart cherry supplementation on acute endurance
531 exercise performance in aerobically trained individuals. *J Int Soc Sports Nutr* 2016,
532 13(22), Epub. Doi: 10.1186/s12970-016-0133-Z
- 533 20. Kang, S.W., Hahn, S., Kim, J.K., Yang, S.M., Park, B.J., & Lee, S.C. Oligomerized
534 lychee fruit extract (OLFE) and a mixture of vitamin C and vitamin E for endurance
535 capacity in a double blind randomized controlled trial. *J Clin Biochem Nutri*, 2012, 50,
536 106-113.
- 537 21. Cook, M.D., Myers, S.D., Blacker, S.D., & Willems, M.E.T. New Zealand
538 Blackcurrant Extract Improves Cycling Performance and Fat Oxidation in Cyclists.
539 *Eur J Appl Physiol*, 2015, 115(11), 2357-2365.
- 540 22. Trinity, JD, Pahnke, MD, Trombold, JR, Coyle, EF. Impact of polyphenol
541 antioxidants on cycling performance and cardiovascular function. *Nutrients*, 2014,
542 6(3), 1273-1292.
- 543 23. Howatson, G, McHugh, MP, Hill, JA, Brouner, J, Jewell, AP, Van Someren, KA,
544 Shave, RE, Howatson, SA Influence of tart cherry juice on indices of recovery
545 following marathon running. *Scand J Med Sci Sports* 2010, 20(6); 843–852.
546 doi:10.1111/j.1600-0838.2009.01005
- 547 24. Bowtell JL, Sumners DP, Dyer A, Fox P, Mileva KN. Montgomery cherry juice
548 reduces muscle damage caused by intensive strength exercise. *Medicine and Science*
549 *in Sports and Exercise*. 2010;43(8):1544–1551.
- 550 25. Manach, C, Williamson, G, Morand, C, Scalbert, A, Rémésy, C. Bioavailability and
551 bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J*
552 *Clin Nutr* 2005, 81; 230-242.

- 553 26. Lauer, T, Preik, M, Rassaf, T, Strauer, BE, Deussen, A, Feelisch, M, Kelm, M.
554 Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase
555 activity but lacks intrinsic vasodilator action. *PNAS* 2001, 98, 22; 12814–12819, doi:
556 10.1073/pnas.221381098.
- 557 27. Grassi, B, Quaresima, V. Near-infrared spectroscopy and skeletal muscle oxidative
558 function in vivo in health and disease: a review from an exercise physiology
559 perspective. *J Biomed Opt* 2016, 21, 091313, doi:10.1117/1.JBO.21.9.091313
- 560 28. Whipp, BJ, Davis, JA, Torres, F, Wasserman, K. A test to determine parameters of
561 aerobic function during exercise. *J Appl Physiol* 1981, 50, 217–221
- 562 29. Wylie, LJ, Mohr, M, Krstrup, P, Jackman, SR, Kelly, EG, Black, MI, Bailey, SJ,
563 Vanhatalo, A, Jones, AM Dietary nitrate supplementation improves team sport-
564 specific intense intermittent exercise performance. *Eur J Appl Physiol* 2013, 113(7);
565 1673-1684.
- 566 30. Astbury, NM, Stevenson, EJ, Morris, P, Taylor, MA, Macdonald, IA Dose-response
567 effect of a whey protein preload on within-day energy intake in lean subjects. *Br J*
568 *Nutr* 2010, 104; 1858–1867. doi: 10.1017/S000711451000293X.
- 569 31. Bailey, SJ, Blackwell, JR, Lord, T, Vanhatalo, A, Winyard, PG, Jones, AM. L-
570 citrulline supplementation improves O₂ uptake kinetics and high-intensity exercise
571 performance in humans. *J Appl Physiol* 2015, 19(4):385–95.
572 doi:10.1152/jappphysiol.00192.2014.
- 573 32. Jeukendrup, A E, Currell, K. Should time trial performance be predicted from three
574 serial time-to-exhaustion tests? *Med. Sci. Sports Exerc*, 2005, 37, 1820. doi:
575 10.1249/01.mss.0000175095.56646.4b
- 576 33. Coakley, S, Passfield, L. Cycling performance is superior for time-to-exhaustion
577 versus time-trial in endurance laboratory tests. *J Sports Sci* 2017, 11,1-7. doi:
578 10.1080/02640414.2017.1368691.
- 579 34. Powers, SK, Deruisseau, KC, Quindry, J, Hamilton, KL. Dietary AOXs and exercise.
580 *J Sports Sci* 2004, 22: 81–94.
- 581 35. MacRae, HSH, Mefferd, KM. Dietary antioxidant supplementation combined with
582 quercetin improves cycling time trial performance. *Int J Sport Nutr Exerc Metab* 2006,
583 16:405–419.
- 584 36. Paschalis, V, Theodorou, AA, Margaritelis, NV, Kyparos, A., Nikolaidis, MG. N-
585 acetylcysteine supplementation increases exercise performance and reduces oxidative
586 stress only in individuals with low levels of glutathione. *Free Radic Biol Med* 2018, 1,
587 115, 288-297.
- 588 37. Reid, MB, Khawli, FA, Moody, MR. Reactive oxygen in skeletal muscle III.
589 Contractility of unfatigued muscle. *J Appl Physiol* 1993, 75; 1081–1087.
- 590 38. Bassett, DR, Howley, ET., Limiting factors for maximum oxygen uptake and
591 determinants of endurance performance. *Med Sci Sports Exerc* 2000, 32, 70-84.
- 592 39. Ziberna, L, Lunder, M, Tramer, F, Drevensek, G, Passamonti, S. The endothelial
593 plasma membrane transporter bilirubin translocase mediates rat aortic vasodilation induced
594 by anthocyanins. *Nutr Metab Cardiovasc Dis* 2013, 23(1), 68-74.
- 595 40. Green, DJ, Maiorana, A, O’Driscoll, G, Taylor, R. Effect of exercise training on
596 endothelium-derived nitric oxide function in humans. *J Physiol* 2004, 561(1); 1-25,
597 doi:10.1112/jphysiol.2004.068197

598 41. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro L.
599 Relaxation of bovine coronary artery and activation of coronary arterial guanylate
600 cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. *J Cyclic*
601 *Nucleotide Res* 1979, 5: 211–224
602